The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ABBVIE INC | Common | 00287Y109 | 344,364 | 3,875,358 | SH | SOLE | 3,875,358 | 0 | 0 | ||
| ALKERMES PLC | SHS | G01767105 | 372,946 | 7,335,683 | SH | SOLE | 7,074,748 | 0 | 260,935 | ||
| BIOGEN INC | Common | 09062X103 | 112,750 | 360,084 | SH | SOLE | 360,084 | 0 | 0 | ||
| BIOVERATIV INC | Common | 09075E100 | 111,876 | 1,960,325 | SH | SOLE | 1,817,975 | 0 | 142,350 | ||
| GILEAD SCIENCES INC | Common | 375558103 | 134,946 | 1,665,592 | SH | SOLE | 1,665,592 | 0 | 0 | ||
| PROTHENA CORP PLC | SHS | G72800108 | 735,114 | 11,349,614 | SH | SOLE | 10,764,540 | 0 | 585,074 | ||
| THERAVANCE BIOPHARMA INC | Common | G8807B106 | 366,577 | 10,706,108 | SH | SOLE | 9,933,109 | 0 | 772,999 | ||